ReviewCell communication and signaling : CCS2026
Harnessing exosomal long non-coding RNAs as a new frontier for molecular diagnostics and therapeutics in diabetes mellitus.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are emerging as dynamic regulators of cellular crosstalk. Exosomal long non-coding RNAs (Exo-lncRNAs) are now recognized as key molecular mediators of diabetes mellitus. These molecules are interrelated with β-cell function, insulin resistance, inflammation, and diabetic complications. Key diabetes-related exo-lncRNAs include exo-P3134, which supports β-cell compensation, as well as exo-MALAT1 and exo-GAS5, which are regulators of insulin resistance and β-cell dysfunction. This review unravels the complex interplay between exo-lncRNAs and the hallmarks of diabetes, across disease pathogenesis and complications. It also spotlights the unprecedented potential of exo-lncRNAs as non-invasive biomarkers and next-generation therapeutic targets in precision medicine in diabetes. By combining mechanistic and translational evidence, this review offers the first integrative framework that positions exo-lncRNAs at the center of diabetes progression and opens new avenues for translational applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.